(Circulation. 2000;102:591.)
© 2000 American Heart Association, Inc.
Current Perspective |
Photoangioplasty
An Emerging Clinical Cardiovascular Role for Photodynamic Therapy
From the Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, Calif (S.G.R., D.P.L.), and Pharmacyclics, Inc, Sunnyvale, Calif (W.-F.C., K.W.W.).
Correspondence to Stanley G. Rockson, MD, Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Dr, CVRC 287, Stanford, CA 94305. E-mail rockson{at}leland.stanford.edu
Abstract—Photodynamic therapy (PDT) has been studied and applied to various disease processes. The potential of PDT for selective destruction of target tissues is especially appealing in cardiovascular disease, in which other existing interventional tools are somewhat nonselective and carry substantial risk of damage to the normal arterial wall. Enthusiasm for photoangioplasty (PDT of vascular de novo atherosclerotic and, potentially, restenotic lesions) is fueled by more effective second-generation photosensitizers and technological advances in endovascular light delivery. This excitement revolves around at least 4 significant attributes of light-activated therapy: the putative selectivity and safety of photoangioplasty, the potential for atraumatic and effective debulking of atheromatous plaque through a biological mechanism, the postulated capability to reduce or inhibit restenosis, and the potential to treat long segments of abnormal vessel by simply using fibers with longer light-emitting regions. The available nonclinical data, coupled with the observations of a new phase I trial in human peripheral atherosclerosis, suggest a promising future for photoangioplasty in the treatment of primary atherosclerosis and prevention of restenosis.
Key Words: photodynamic therapy • photoangioplasty • atherosclerosis • restenosis
This article has been cited by other articles:
 |
|
 |
|
  R Waksman, I M Leitch, J Roessler, H Yazdi, R Seabron, F Tio, R W Scott, R I Grove, S Rychnovsky, B Robinson, et al. Intracoronary photodynamic therapy reduces neointimal growth without suppressing re-endothelialisation in a porcine model Heart, August 1, 2006; 92(8): 1138 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Cotton A Review of the Principles and Use of Lasers in Lower Limb Problems International Journal of Lower Extremity Wounds, September 1, 2004; 3(3): 133 - 142. [Abstract] [PDF]
|
|
|
|
 |
|
 N. R. Bijsterveld, R. J. G. Peters, S. A. Murphy, P. J. L. M. Bernink, J. G. P. Tijssen, M. Cohen, and TIMI 11B/ESSENCE Study Groups Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: Results from the thrombolysis in myocardial infarction (TIMI) 11B and efficacy and safety of subcutaneous enoxaparin in Non-Q-Wave coronary events (ESSENCE) studies J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2083 - 2089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kereiakes, A. M. Szyniszewski, D. Wahr, H. C. Herrmann, D. I. Simon, C. Rogers, P. Kramer, W. Shear, A. C. Yeung, K. A. Shunk, et al. Phase I Drug and Light Dose-Escalation Trial of Motexafin Lutetium and Far Red Light Activation (Phototherapy) in Subjects With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention and Stent Deployment: Procedural and Long-Term Results Circulation, September 16, 2003; 108(11): 1310 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A Thompson and S. N Oesterle Biointerventional cardiology: the future interface of interventional cardiovascular medicine and bioengineering Vascular Medicine, May 1, 2002; 7(2): 135 - 140. [Abstract] [PDF]
|
|
|
|
|
|
N. R. Bijsterveld, A. H. Moons, J. C. M. Meijers, J. G. P. Tijssen, H. R. Buller, M. Levi, and R. J. G. Peters Rebound thrombin generation after heparin therapy in unstable angina: A randomized comparison between unfractionated and low-molecular-weight heparin J. Am. Coll. Cardiol., March 6, 2002; 39(5): 811 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Arakawa, K. Hagisawa, H. Kusano, S. Yoneyama, A. Kurita, T. Arai, M. Kikuchi, I. Sakata, S.-i. Umenura, and F. Ohsuzu Sonodynamic Therapy Decreased Neointimal Hyperplasia After Stenting in the Rabbit Iliac Artery Circulation, January 15, 2002; 105(2): 149 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Granville, B. A. Cassidy, D. O. Ruehlmann, J. C. Choy, C. Brenner, G. Kroemer, C. van Breemen, P. Margaron, D. W. Hunt, and B. M. McManus Mitochondrial Release of Apoptosis-Inducing Factor and Cytochrome c During Smooth Muscle Cell Apoptosis Am. J. Pathol., July 1, 2001; 159(1): 305 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Chen, K. W. Woodburn, C. Shi, D. C. Adelman, C. Rogers, and D. I. Simon Photodynamic Therapy With Motexafin Lutetium Induces Redox-Sensitive Apoptosis of Vascular Cells Arterioscler. Thromb. Vasc. Biol., May 1, 2001; 21(5): 759 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Stief Is Singlet Oxygen Antiatherosclerotic? Am. J. Pathol., February 1, 2001; 158(2): 781 - 782. [Full Text] [PDF]
|
|
|
|
|
|
S. G. Rockson, P. Kramer, M. Razavi, A. Szuba, S. Filardo, P. Fitzgerald, J. P. Cooke, S. Yousuf, A. R. DeVault, M. F. Renschler, et al. Photoangioplasty for Human Peripheral Atherosclerosis : Results of a Phase I Trial of Photodynamic Therapy With Motexafin Lutetium (Antrin) Circulation, November 7, 2000; 102(19): 2322 - 2324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Villard, M. D. Feldman, J. Kim, T. E. Milner, and G. L. Freeman Use of a Blood Substitute to Determine Instantaneous Murine Right Ventricular Thickening With Optical Coherence Tomography Circulation, April 16, 2002; 105(15): 1843 - 1849. [Abstract] [Full Text] [PDF]
|
|